Metrion Biosciences (“Metrion”), the specialist preclinical contract research organization (CRO) and a global leader in ion channel services, today announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics.
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2025 Diabetes Prevention Awareness Center.